Abelacimab slashes bleeding risk by 67 percent in people with A-Fib
By
Kristen
Kristen Fischer
Nov 14, 2023
Abelacimab, an experimental anti-clotting drug, was effective at lowering bleeding in people with atrial fibrillation (A-Fib) who were at risk of having a stroke compared with a competing drug, according...
Clinical briefs for Thursday, Nov. 2
By
Kristen Fischer
Nov 02, 2023
Paxlovid didn’t help older adults with long COVID, study shows … What geriatricians should know about monoclonal anti-amyloid antibodies for Alzheimer’s … High salt linked to type 2 diabetes...
Not all older adults can get monoclonal antibodies for Alzheimer’s disease, study finds
By
Kristen Fischer
Sep 22, 2023
Even though newer monoclonal antibodies are available for Alzheimer’s disease, there are limits on the number of older adults who can receive them, a recent study published in Neurology finds.
Clinical briefs for Tuesday, Sept. 12
By
Kristen Fischer
Sep 12, 2023
Feds make deal with Regeneron on more COVID-19 monoclonal antibodies … These “secrets” help people in blue zones live longer … What it’ll take to make Alzheimer’s blood tests routine … Study...
Also in the News for Tuesday, Sept. 12
By
Kimberly Marselas
Sep 12, 2023
HHS reaches agreement with drugmaker on next generation of COVID treatments favored by nursing homes … Take blood pressure readings while patient lies down for better risk prediction: AHA … Encouraging...
Report: Nursing homes underused COVID-19 antiviral drugs during pandemic
By
Kristen Fischer
Jul 17, 2023
Even though oral antiviral drugs and monoclonal antibodies help people recover from COVID-19, a new report found that nursing homes didn’t use the medications much during the pandemic.
COVID-19 drug guards against all variants
May 02, 2023
Trial results for AstraZeneca’s experimental antibody, a potential replacement for Evusheld, could be out by September. The company is hoping for emergency use authorization by the end of 2023.
Eli Lilly expects Medicare about-face on Alzheimer’s drugs coverage
By
Alicia Lasek
Apr 23, 2023
New data on Lilly’s experimental drug donanemab may influence CMS’s restrictive stance on coverage of this and other amyloid-busting Alzheimer’s treatments, a company executive says.
Monoclonal antibodies ‘unequivocally’ saved lives during pandemic, patient data show
By
Alicia Lasek
Apr 14, 2023
For two years, monoclonal antibodies were approved, revoked and sometimes reauthorized or scarce, but pushing through these challenges “unequivocally saved lives and prevented hospitalizations,”...
Senators blast HHS’ restrictive coverage for Alzheimer’s drugs
By
Ron Rajecki
Mar 24, 2023
Health and Human Services Secretary Xavier Becerra came under fire Wednesday during a Senate Finance Committee meeting regarding the Centers for Medicare & Medicaid Services’ restrictive national...